Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

Registry ID

EUCTR2010-020447-13

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2012-08-17

Completion date

2015-05-05

Last update

2026-08-16

Conditions

• Metastatic Renal Cell Carcinoma

Summary

To assess the progression-free survival (PFS) in patients who receive everolimus as second-line treatment for metastatic renal cell carcinoma

Locations

• , , Bulgarian Drug Agency

Related clinical trials

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
• Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
• Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
• Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

View on source registry